Applied to medicines, price controls would translate into shortages and slow, or non-existent, introduction of new, ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Investing Intel. In this article, we will summarize ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Merck KGaA led the way in pharmaceutical M&A in April. The German company announced a $3.9 billion deal to buy the US drug ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

While Merck's earnings were... SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...